Clinical Trial Update: Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intravitreal APL-2 vs sham injections in geographic atrophy due to age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• APL-2 (pegylated C3 inhibitor)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2023-06-18